{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:39:15Z","timestamp":1792525155359,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104829","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:15:27Z","timestamp":1791414927000},"page":"104829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic review of EU and US product labels containing real world data in support of efficacy claims"],"prefix":"10.1016","volume":"31","author":[{"given":"Ana Gl\u00f3ria","family":"Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9590-1191","authenticated-orcid":false,"given":"Chiara","family":"Rancan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Cerruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Falconnier-Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Falconnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104829_b0005","unstructured":"US Food and Drug Administration. Framework for FDA\u2019s Real-world Evidence Program. www.fda.gov\/media\/120060\/download. Published December, 2018. Accessed November 3, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cpt.1426","article-title":"Real-world data for regulatory decision making: challenges and possible solutions for Europe","volume":"106","author":"Cave","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104829_b0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cpt.2461","article-title":"Marketing authorization applications made to the European Medicines Agency in 2018\u20132019: what was the contribution of real-world evidence?","volume":"111","author":"Flynn","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104829_b0020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1208\/s12248-025-01082-1","article-title":"Application of real-world evidence to support FDA regulatory decision making","volume":"27","author":"Khaowroongrueng","year":"2025","journal-title":"AAPS J"},{"key":"10.1016\/j.drudis.2026.104829_b0025","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMp2200089","article-title":"Real-world evidence \u2014 where are we now?","volume":"386","author":"Concato","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104829_b0030","doi-asserted-by":"crossref","first-page":"e5715","DOI":"10.1002\/pds.5715","article-title":"When can real-world data generate real-world evidence?","volume":"33","author":"Rahman","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.drudis.2026.104829_b0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/ehjqcco\/qcad009","article-title":"Real world evidence: perspectives from a European Society of Cardiology cardiovascular round table with contribution from the European Medicines Agency","volume":"9","author":"Szyma\u0144ski","year":"2023","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.drudis.2026.104829_b0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cpt.2474","article-title":"The role of real-world evidence in FDA-approved new drug and biologics license applications","volume":"111","author":"Purpura","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104829_b0045","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), and Oncology Center for Excellence (OCE). Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory. Updated July 25, 2024. Accessed November 4, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0050","unstructured":"U.S. Food and Drug Administration, Oncology Center of Excellence (OCE), Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER). Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/real-world-evidence-considerations-regarding-non-interventional-studies-drug-and-biological-products. Published March, 2024. Updated April 8, 2024. Accessed November 4, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0055","unstructured":"Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Oncology Center of Excellence (OCE). Real-World Data: Assessing Registries To Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/real-world-data-assessing-registries-support-regulatory-decision-making-drug-and-biological-products. Published December, 2023. Accessed November 4, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0060","unstructured":"Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Data Standards for Drug and Biological Product Submissions Containing Real-World Data Guidance for Industry. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/data-standards-drug-and-biological-product-submissions-containing-real-world-data. Published December, 2023. Accessed November 4, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0065","unstructured":"Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Oncology Center of Excellence (OCE). Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug. Published August, 2023. Accessed November 4, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0070","unstructured":"Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Oncology Center of Excellence (OCE). Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products. Published February, 2023. Accessed November 4, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0075","unstructured":"Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drug-and-biological-products. Published September, 2022. Accessed November 4, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0080","unstructured":"European Medicines Agency. Reflection Paper on Use of Real-world Data in Non-interventional Studies to Generate Real-world Evidence \u2014 Scientific Guideline. www.ema.europa.eu\/en\/reflection-paper-use-real-world-data-non-interventional-studies-generate-real-world-evidence-scientific-guideline. Published April 3, 2025. Accessed November 4, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0085","unstructured":"European Medicines Agency. Establishing Efficacy Based on Single-arm Trials Submitted as Pivotal Evidence in a Marketing Authorisation \u2014 Scientific Guideline. www.ema.europa.eu\/en\/establishing-efficacy-based-single-arm-trials-submitted-pivotal-evidence-marketing-authorisation. Published September 16, 2024. Accessed November 4, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0090","unstructured":"European Medicines Agency. Guideline on Registry-based Studies \u2014 Scientific Guideline. www.ema.europa.eu\/en\/guideline-registry-based-studies-scientific-guideline. Published October 26, 2021. Accessed November 4, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0095","doi-asserted-by":"crossref","unstructured":"US Food & Drugs Administration. FDA Use of Real-World Evidence in Regulatory Decision Making. www.fda.gov\/science-research\/real-world-evidence\/fda-use-real-world-evidence-regulatory-decision-making. Published September 26, 2025. Accessed January 27, 2026.","DOI":"10.1208\/s12248-025-01082-1"},{"key":"10.1016\/j.drudis.2026.104829_b0100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/cpt.2272","article-title":"Understanding use of real-world data and real-world evidence to support regulatory decisions on medical product effectiveness","volume":"111","author":"Mahendraratnam","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104829_b0105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13023-024-03111-2","article-title":"A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases","volume":"19","author":"Vaghela","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104829_b0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/1078-0432.CCR-21-2639","article-title":"Real-world evidence in support of oncology product registration: a systematic review of new drug application and biologics license application approvals from 2015\u20132020","volume":"28","author":"Arondekar","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104829_b0115","doi-asserted-by":"crossref","DOI":"10.1002\/bcp.70471","article-title":"Through the lens of marketing authorization holders: experience in use of real-world data and real-world evidence in drug development and regulatory submissions in EU","author":"Eskola","year":"2026","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104829_b0120","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2462","article-title":"Use of real-world data and evidence in drug development of medicinal products centrally authorized in Europe in 2018\u20132019","volume":"111","author":"Eskola","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104829_b0125","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.12688\/f1000research.12198.1","article-title":"An analysis of characteristics of post-authorisation studies registered on the ENCePP EU PAS Register","volume":"6","author":"Carroll","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.drudis.2026.104829_b0130","unstructured":"Dr Evidence. www.drevidence.com\/. Accessed November 4, 2025."},{"issue":"24","key":"10.1016\/j.drudis.2026.104829_b0135","first-page":"75","article-title":"FDA approvals","volume":"2025","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104829_b0140","unstructured":"European Medicines Agency (EMA). Annual Report 2024. www.ema.europa.eu\/assets\/en\/annual-report\/2024\/index.html. Published, 2025. Accessed November 4, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0145","unstructured":"European Medicines Agency. Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron). www.ema.europa.eu\/en\/medicines\/human\/EPAR\/qarziba. Published March 5, 2018. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0150","unstructured":"European Medicines Agency. Holoclar. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/holoclar. Published June 22, 2017. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0155","unstructured":"US Food and Drugs Administration. Drugs@FDA: FDA-Approved Drugs. Vijoice. www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=215039. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/1078-0432.CCR-23-1270","article-title":"FDA approval summary: Alpelisib for PIK3CA-related overgrowth spectrum","volume":"30","author":"Singh","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104829_b0165","unstructured":"Pazdur R. FDA Approves Alpelisib for PIK3CA-related Overgrowth Spectrum. www.asco.org\/news-initiatives\/policy-news-analysis\/fda-approves-alpelisib-pik3ca-related-overgrowth-spectrum. Published April 6, 2022. Accessed May 6, 2026."},{"key":"10.1016\/j.drudis.2026.104829_b0170","unstructured":"European Medicines Agency. Vijoice. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vijoice. Published May 22, 2026. Accessed September 4, 2026."},{"key":"10.1016\/j.drudis.2026.104829_b0175","unstructured":"US Food and Drugs Administration. Drugs@FDA: FDA-Approved Drugs. Carbaglu. www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0180","unstructured":"European Medicines Agency. Tecartus. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecartus. Published January 25, 2021. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0185","unstructured":"European Medicines Agency. Yescarta. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yescarta. Published August 23, 2018. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0190","unstructured":"National Cancer Institute. SEER-Medicare: Brief Description of SEER-Medicare Database. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/overview\/. Updated May 16, 2019. Accessed November 5, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0195","unstructured":"European Medicines Agency. Tecentriq. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecentriq. Published August 9, 2018. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0200","unstructured":"European Medicines Agency. Brineura. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/brineura. Published December 7, 2017. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0205","unstructured":"US Food and Drugs Administration. Drugs@FDA: FDA-Approved Drugs. Brineura. www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0210","unstructured":"US Food and Drugs Administration. Drugs@FDA: FDA-Approved Drugs. Fabrazyme. www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0215","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jamaoncol.2022.5985","article-title":"Use of single-arm trials for US Food and Drug Administration drug approval in oncology, 2002\u20132021","volume":"9","author":"Agrawal","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.drudis.2026.104829_b0220","unstructured":"European Medicines Agency. Raxone. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/raxone. Published March 8, 2018. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0225","unstructured":"European Medicines Agency. Fabrazyme. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fabrazyme. Published February 1, 2018. Accessed September 4, 2026."},{"key":"10.1016\/j.drudis.2026.104829_b0230","unstructured":"European Medicines Agency. NexoBrid. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nexobrid. Published August 9, 2018. Accessed September 4, 2026."},{"key":"10.1016\/j.drudis.2026.104829_b0235","unstructured":"US Food and Drugs Administration. Drugs@FDA: FDA-Approved Drugs. Orencia. www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0240","unstructured":"US Food and Drugs Administration. Drugs@FDA: FDA-Approved Drugs. Soliris. www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0245","unstructured":"European Medicines Agency. Defitelio. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/defitelio. Published April 21, 2017. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0250","unstructured":"US Food and Drugs Administration. Drugs@FDA: FDA-Approved Drugs. Exondys 51. www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed September 4, 2026."},{"key":"10.1016\/j.drudis.2026.104829_b0255","unstructured":"US Food & Drugs Administration. April 25, 2016: Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee. https:\/\/web.archive.org\/web\/20200803205351\/https:\/\/www.fda.gov\/advisory-committees\/april-25-2016-meeting-peripheral-and-central-nervous-system-drugs-advisory-committee-04252016. Published August 25, 2016. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0260","unstructured":"European Union. Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use. Vol 311. 2001. http:\/\/data.europa.eu\/eli\/dir\/2001\/83\/oj. Accessed November 5, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0265","unstructured":"UK Secretary of State and the Minister for Health, Social Services and Public Safety. The Human Medicines Regulations 2012. www.legislation.gov.uk\/uksi\/2012\/1916\/regulation\/54. Accessed November 5, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0270","unstructured":"European Medicines Agency. Libmeldy. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/libmeldy. Published December 22, 2020. Updated December 16, 2025. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0275","unstructured":"US Food and Drugs Administration. Lenmeldy. www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/lenmeldy. Updated July 23, 2025. Accessed November 24, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0280","unstructured":"European Medicines Agency. Myozyme. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/myozyme. Published September 7, 2009. Updated August 16, 2024. Accessed September 4, 2026."},{"key":"10.1016\/j.drudis.2026.104829_b0285","unstructured":"US Food and Drugs Administration. Drugs@FDA: FDA-Approved Drugs. Lumizyme. www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed September 4, 2026."},{"key":"10.1016\/j.drudis.2026.104829_b0290","unstructured":"US Food and Drugs Administration. Drugs@FDA: FDA-Approved Drugs. Nulibry. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed September 4, 2026."},{"key":"10.1016\/j.drudis.2026.104829_b0295","unstructured":"European Medicines Agency. Nulibry. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nulibry. Published September 29, 2022. Updated July 25, 2024. Accessed September 4, 2026."},{"key":"10.1016\/j.drudis.2026.104829_b0300","unstructured":"European Medicines Agency. Strensiq. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/strensiq. Published September 28, 2015. Updated November 26, 2018. Accessed September 4, 2026."},{"key":"10.1016\/j.drudis.2026.104829_b0305","unstructured":"US Food and Drugs Administration. Drugs@FDA: FDA-Approved Drugs. Strensiq. www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process. Accessed September 4, 2026."},{"key":"10.1016\/j.drudis.2026.104829_b0310","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cpt.3700","article-title":"US Food and Drug Administration\u2019s advancing real-world evidence program: initial experience","volume":"118","author":"Smith","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104829_b0315","unstructured":"National Archives. Code of Federal Regulations. Title 21. \u00a7 314.126. Adequate and well-controlled studies. www.ecfr.gov\/current\/title-21\/part-314\/section-314.126. Updated September 22, 2026. Accessed November 10, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0320","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products\u2014Content and Format. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-studies-section-labeling-human-prescription-drug-and-biological-products-content-and-format. Published January, 2006. Updated January 31, 2025. Accessed October 11, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0325","unstructured":"European Commission. A Guideline on Summary of Product Characteristics (SmPC). https:\/\/health.ec.europa.eu\/document\/download\/6a043dea-7d0f-4252-947b-cef58f53d37e_en. Published September, 2009. Accessed October 11, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0330","unstructured":"European Medicines Agency. Assessment of SmPC Section 5.1: A Guide for Assessors of Centralised Applications\u2014Scientific Guideline. www.ema.europa.eu\/en\/assessment-smpc-section-51-guide-assessors-centralised-applications-scientific-guideline. Published December 18, 2023. Accessed November 4, 2025."},{"key":"10.1016\/j.drudis.2026.104829_b0335","unstructured":"European Medicines Agency. ICH M15 Guideline on General Principles for Model-informed Drug Development\u2014Scientific Guideline. www.ema.europa.eu\/en\/ich-m15-guideline-general-principles-model-informed-drug-development-step-2b-scientific-guideline. Published February 11, 2026. Accessed May 7, 2026."},{"key":"10.1016\/j.drudis.2026.104829_b0340","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jclinepi.2022.11.007","article-title":"Regulatory agencies disregard real-world effectiveness evidence on product labels beyond what is reasonable","volume":"153","author":"Dal-R\u00e9","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.drudis.2026.104829_b0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19466315.2023.2190931","article-title":"Combining the Target trial and Estimand frameworks to define the causal Estimand: an application using real-world data to contextualize a single-arm trial","volume":"16","author":"Hampson","year":"2024","journal-title":"Stat Biopharm Res"},{"key":"10.1016\/j.drudis.2026.104829_b0350","unstructured":"European Medicines Agency. Navigating Priorities from Regulatory Perspective. EFSPI Regulatory Statistics Workshop 2025. https:\/\/efspieurope.github.io\/workshop\/data\/2025\/slides\/01_Overture_1_Roes.pdf. Published September, 2025. Accessed May 7, 2026."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:50:30Z","timestamp":1792522230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002345"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104829","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of EU and US product labels containing real world data in support of efficacy claims","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104829"}}